Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
As of February 2022, more than 100 patients with NRG1 gene fusion positive ("NRG1+") cancer have been treated with zenocutuzumab ("Zeno") monotherapy Clinical data updates planned for lead program Zeno in 1H22 and for petosemtamab ("MCLA-158") and MCLA-129 in 2H22 Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations beyond 2024 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced finan
